Sunday, June 2, 2019, Chicago, Illinois, 7:00 PM - 9:30 PM

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bruce D Cheson, MD
Frank M Ewing Foundation Chair in Hematology-Oncology
Professor of Medicine
Head of Hematology and Cellular Therapy
Deputy Chief, Division of Hematology-Oncology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Ann S LaCasce, MD, MMSc
Program Director, Dana-Farber/Partners Fellowship
in Hematology/Oncology
Associate Professor of Medicine
Institute Physician
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Oncopeptides and Seattle Genetics.
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Agenda and Format

This unique activity will feature 3 separate content modules during which a pair of noted investigators will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Multiple Myeloma (MM) — Dr Raje and Dr Richardson

  • Published research evidence with the use of lenalidomide for high-risk smoldering MM
  • Correlation between minimal residual disease (MRD) negativity and long-term outcomes for patients with newly diagnosed MM undergoing active treatment; current role of MRD assessment in routine practice
  • Key findings from the Phase III MAIA trial evaluating lenalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM who are not candidates for autologous stem cell transplant (ASCT); potential clinical role
  • Design, eligibility criteria and outcomes from the Phase III TOURMALINE-MM3 trial comparing ixazomib to placebo as maintenance therapy after ASCT
  • Optimal selection, sequencing and combining of available agents (eg, carfilzomib, pomalidomide, daratumumab, elotuzumab, ixazomib and panobinostat) for patients with relapsed/refractory (R/R) disease
  • FDA approval of a split-dosing regimen for daratumumab; emerging Phase III findings from the COLUMBA trial evaluating a subcutaneous formulation of daratumumab
  • Published research experience with BCMA-targeted chimeric antigen receptor (CAR) T-cell therapies in MM
  • Early efficacy data with venetoclax for patients with R/R MM; recent FDA hold on ongoing trials evaluating venetoclax
  • Emerging Phase III data documenting the efficacy and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for R/R MM
  • Published efficacy and safety data with and ongoing Phase III evaluation of melflufen for multiagent-refractory MM
  • Other promising agents and strategies under investigation

MODULE 2: Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL) — Dr Cheson and Dr LaCasce

  • Implications of recent Phase III data comparing ibrutinib (with or without rituximab) to standard chemoimmunotherapy for younger (ECOG-E1912) and older (Alliance A041202) patients with treatment-naïve CLL
  • Outcomes from the Phase III iLLUMINATE trial comparing ibrutinib/obinutuzumab to chlorambucil/obinutuzumab for treatment-naïve CLL; recent FDA approval of ibrutinib/obinutuzumab and patient selection for its use
  • Results from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical and research implications
  • Published efficacy and safety experience with acalabrutinib in treatment-naïve and progressive CLL; current nonresearch role for patients with CLL who are not candidates for ibrutinib
  • Emerging findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL
  • Long-term follow-up from the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab (BR) for R/R CLL; practical integration of venetoclax into practice
  • Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL (eg, FLAIR, CLL13 [GAIA], CLL3011 [GLOW], ACE-CL-007 [Elevate CLL TN])
  • Clinical and research implications of Phase III trials (RELEVANCE, AUGMENT) evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed and R/R FL
  • Role of obinutuzumab-based induction and maintenance therapy for previously untreated FL; integration of obinutuzumab into current algorithms for treatment-naïve and R/R disease
  • Patient selection for PI3 kinase inhibition in R/R FL; appropriate integration of idelalisib, copanlisib and duvelisib into current management algorithms

MODULE 3: Hodgkin Lymphoma (HL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) and T-Cell Lymphoma (TCL) — Dr Abramson and Dr Smith

  • Recent FDA approval of brentuximab vedotin (BV) in combination with doxorubicin/vinblastine/dacarbazine as first-line therapy for advanced classical HL; experience with North American patients in the ECHELON-1 trial and implications, if any, for the adoption of BV
  • Early data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, BV) for newly diagnosed or R/R HL
  • Recent FDA approval of BV in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral TCLs; diagnostic and clinical implications
  • Early activity and safety data with ibrutinib alone or in combination with other systemic therapies for previously untreated MCL; ongoing and planned Phase III trials (eg, TRIANGLE, SHINE, SYMPATICO)
  • Research database supporting the FDA approval of acalabrutinib in R/R MCL; patient selection for its use
  • Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in R/R MCL
  • Longer-term follow-up from clinical trials of approved and investigational CAR T-cell platforms; appropriate referral for consideration of CAR T-cell therapy in general practice
  • Clinical and research implications of emerging results from the Phase III ROBUST trial evaluating lenalidomide in combination with R-CHOP as first-line therapy for patients with activated B-cell-type DLBCL
  • Available efficacy and safety data with the use of polatuzumab vedotin in combination with BR for patients with R/R DLBCL; FDA breakthrough therapy designation for and ongoing Phase III evaluation of polatuzumab vedotin
  • FDA approval of pembrolizumab for R/R primary mediastinal large B-cell lymphoma; future development plans for immune checkpoint inhibition in this disease

Target Audience:
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile and psychosocial status.
  • Evaluate existing and emerging clinical research data to formulate therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and T-cell lymphoma.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Customize induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with R/R MM.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and/or potential utility of each in clinical practice.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies in the management of HL, NHL, CLL and MM to support quality of life and continuation of treatment.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Oncopeptides and Seattle Genetics.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM on Sunday, June 2nd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.